Patent ID: 11912780
Assignee: ACTINIUM PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method for depleting a human subject's hematopoietic stem cells in preparation for administration of a genetically edited hematopoietic stem cell therapy, the method consisting essentially of administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, wherein the radiolabeled anti-CD45 antibody is radiolabeled BC8 comprising 131I or 225Ac,
wherein the subject is afflicted with a non-cancerous disorder treatable via genetically edited hematopoietic stem cell therapy,
wherein the non-cancerous disorder is selected from the group consisting of a hemoglobinopathy, a congenital immunodeficiency, and a viral infection,
wherein depleting the subject's hematopoietic stem cells consists of reducing a population of hematopoietic stem cells in the subject by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99%, and wherein
(i) the radiolabeled BC8 is 131I-BC8, and the effective amount of 131I-BC8 is from 10 mCi to 1,200 mCi, or
(ii) the radiolabeled BC8 is 225Ac-BC8, and the effective amount of 225Ac-BC8 is selected from the group consisting of from 0.1 μCi/kg to 5.0 μCi/kg subject weight, from 0.1 μCi/kg to 1.0 μCi/kg subject weight, from 1.0 μCi/kg to 3.0 μCi/kg subject weight, and from 3.0 μCi/kg to 5.0 μCi/kg subject weight.